Epic Sciences to present on characterizing PD-L1 in circulating tumor cells on non-small cell lung cancer patients at the 26th EORTC-NCI-AARC Symposium.
Epic Sciences will present an analysis of PD-L1 protein expression on circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients. The poster presentation will take place November 19 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Because tumor biopsy material is often limited in lung cancer patients, Epic developed a new assay that detects PD-L1 protein on CTCs in a blood sample. Novel immunotherapies targeting PD-L1, and its receptor PD-1, have demonstrated efficacy in clinical studies for a number of cancers. Consequently, a test to accurately quantify PD-L1 expression in a liquid biopsy may help identify patients more likely to respond to therapy.
“Accurately identifying and characterizing PD-L1 protein expression using Epic’s CTC technology could provide important insights into therapeutic response and disease progression to support the clinical development of new PD-1 and PD-L1 therapies,” said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. “The benefit in Epic’s “no cell left behind” technology is that we can develop very sensitive and specific biomarker tests that can also provide unique information about the cellular localization of biomarkers.”
“The PD-L1 test we developed on Epic’s CTC platform can not only identify PD-L1 protein levels in traditional CTCs, but also in epithelial plastic CTC subpopulations dramatically improving the sensitivity of the test,” said Ryan Dittamore, vice president, marketing and translational research of Epic Sciences. “Knowing which CTC subpopulations express PD-L1 is important for understanding potential mechanisms of resistance and further analysis of pharmacodynamics in the setting of PD-1 or PD-L1 therapy.”
Details of the presentation are as follows:
- Date/Time: Wednesday, November 19, 6 pm to 7:30 pm CET
- Title: Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patients
- Presenter: R. Dittamore
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Stay in touch on LinkedIn, on Twitter@EpicSciences and Facebook.com/EpicSciences.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., email@example.com,+1.858.344.8091